Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial

Thi Yen Loan Le1, Mahidi Mardini, Viive M Howell

  • 1Department of Cardiology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Insights

Low-dose mineralocorticoid receptor antagonists protect the heart by preventing cardiomyocyte death and reducing infarct size. These drugs work by preserving the apoptosis repressor with caspase recruitment domain, a key protein in regulating cell death pathways.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Pharmacology

Background:

  • Mineralocorticoid receptor antagonists (MRAs) are vital in treating heart failure and myocardial infarction.
  • Apoptosis significantly contributes to cardiac dysfunction and post-infarction remodeling.
  • The role of MRAs in modulating cardiomyocyte apoptosis, particularly via the apoptosis repressor with caspase recruitment domain (ARC), remains under investigation.

Purpose of the Study:

  • To investigate whether low-dose MRAs can prevent cardiomyocyte apoptosis by regulating ARC.
  • To determine the effect of MRAs on infarct size and cardiac remodeling following ischemia-reperfusion injury.
  • To elucidate the molecular mechanisms by which MRAs influence ARC stability and apoptosis.

Main Methods:

  • Ex vivo rat heart model subjected to regional ischemia and reperfusion.
  • Administration of low-dose spironolactone or eplerenone.
  • Assessment of infarct size, apoptosis markers (caspase activation, DNA fragmentation), and ARC protein levels.
  • In vitro studies using H9c2 cells to examine aldosterone-induced apoptosis and ARC degradation.

Main Results:

  • Low-dose spironolactone and eplerenone significantly reduced infarct size in the ex vivo heart model.
  • MRAs prevented ischemia-reperfusion-induced activation of caspases 2, 3, and 9, and abrogated DNA fragmentation.
  • MRAs preserved ARC protein levels, inhibited aldosterone-induced ARC degradation, and reduced cardiomyocyte apoptosis.
  • Aldosterone promotes ARC degradation via the ubiquitin-proteasomal pathway, a process inhibited by MRAs.

Conclusions:

  • Low-dose MRAs effectively reduce myocardial infarct size and apoptosis in a post-ischemia/reperfusion setting.
  • The cardioprotective effects of MRAs are mediated, at least in part, by preventing ARC degradation and subsequent cardiomyocyte death.
  • These findings highlight a novel mechanism for MRA action in cardiovascular disease, targeting the intrinsic apoptotic pathway via ARC stabilization.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...